1. Opening Hook
Cipla’s Q3 concall felt like a farewell speech, a succession plan, and a damage-control briefing rolled into one. Revlimid finally packed its bags, Lanreotide tripped over a USFDA cable, and margins decided to take the stairs down instead of the elevator. Yet, management showed up smiling, armed with peptides, inhalers, and optimism strong enough to qualify as a chronic therapy.
India kept humming, the US stumbled but didn’t faceplant, and R&D bills arrived with no discounts applied. Somewhere between “temporary disruption” and “largest product after Revlimid,” Cipla asked investors to stay calm and read the footnotes.
Stick around—because the real story isn’t the quarter gone by, but the pipeline that management swears will make everyone forget Revlimid ever existed.
2. At a Glance
- Revenue flat YoY at ₹7,074 cr – Revlimid exited stage left; base business tried to clap politely.
- EBITDA margin at 17.7% – When high-margin drugs leave, spreadsheets start sweating.
- R&D spend up 37% YoY – Innovation is expensive, especially when you buy APIs in bulk.
- PAT at ₹676 cr – Includes a ₹276 cr labour-code surprise, courtesy of policy updates.
- Net cash ₹10,229 cr – Still rich enough to absorb a few regulatory hiccups.
3. Management’s Key Commentary
“We delivered revenues of over ₹7,000 crores despite the known drop in generic Revlimid sales.”
(Translation: Revlimid is gone, please stop asking about it 😏)
“Respiratory crossed ₹5,000
